StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Candel Therapeutics's total assets was $208.15M at Jun 30, 2026. For fiscal 2025 it was $125.20M, up 17.2% from the year before. The highest annual figure on record is $125.20M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$125.20M+17.2%
FY2024Dec 31, 2024$106.87M+159.4%
FY2023Dec 31, 2023$41.20M-47.0%
FY2022Dec 31, 2022$77.69M-12.9%
FY2021Dec 31, 2021$89.21M+133.0%
FY2020Dec 31, 2020$38.28M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$208.15M+96.4%
Q1 FY2026Mar 31, 2026$201.92M+110.5%
Q4 FY2025Dec 31, 2025$125.20M+17.2%
Q3 FY2025Sep 30, 2025$93.60M+335.0%
Q2 FY2025Jun 30, 2025$105.97M+300.1%
Q1 FY2025Mar 31, 2025$95.91M+207.2%
Q4 FY2024Dec 31, 2024$106.87M+159.4%
Q3 FY2024Sep 30, 2024$21.52M-57.0%
Q2 FY2024Jun 30, 2024$26.49M-54.9%
Q1 FY2024Mar 31, 2024$31.22M-53.6%
Q4 FY2023Dec 31, 2023$41.20M-47.0%
Q3 FY2023Sep 30, 2023$50.06M-41.1%
Q2 FY2023Jun 30, 2023$58.71M-37.1%
Q1 FY2023Mar 31, 2023$67.24M-33.8%
Q4 FY2022Dec 31, 2022$77.69M-12.9%
Q3 FY2022Sep 30, 2022$85.01M-11.4%
Q2 FY2022Jun 30, 2022$93.30M+203.5%
Q1 FY2022Mar 31, 2022$101.56M+165.3%
Q4 FY2021Dec 31, 2021$89.21M–
Q3 FY2021Sep 30, 2021$95.96M–
Q2 FY2021Jun 30, 2021$30.74M–
Q4 FY2020Dec 31, 2020$38.28M–

More Candel Therapeutics figures

See a number that looks wrong?